Skip to Main Content
New Patients:
0800 564 2270
Alexandra Page - Lab Manager - Care Fertility London using caremaps to monitor embryos in IVF lab

Caremaps -AI Embryo Selection

Selecting the embryo with the most potential is one of the most important elements in IVF treatment. Caremaps-AI®, our time-lapse imaging technique powered by artificial intelligence, has been designed to help us choose the embryo with the most potential without genetic testing.

CareMaps-AI Embryo Selection

Care Fertility scientists have undertaken extensive research for over a decade to improve the accuracy of embryo selection. This resulted in models, or algorithms to select embryos with the highest chance of becoming a baby. Care’s work in this area has been widely published and our latest development uses Machine Learning to analyse embryo development from fertilisation right up to the point of embryo transfer.

Caremaps-AI® time-lapse embryo imaging is unique to Care and is available at all our clinics. 

How did Care produce an artificial intelligence tool (Caremaps-AI®) to analyse embryo development to predict the chance of a birth?

Could Caremaps-AI® be right for me?

Benefits of Caremaps-AI®

Are there any risks?

This technology is safe and non invasive. It assesses images of embryos which are already being collected and the model was trained on Care’s own extensive high quality data. There is increasing evidence supporting the application of Machine Learning to utilise big data from time-lapse imaging and fertility care generally. Whilst promising benefits to IVF patients, responsible use of data is required alongside large high-quality datasets, and rigorous validation, to ensure safe and robust applications.

The independent regulator of fertility treatment, the Human Fertilisation and Embryology Authority (HFEA), has developed a ‘red-amber-green’ rating system and provides information on their website about treatments that are offered on top of your routine fertility treatment – known as treatment add-ons. They consider that the only way to be confident that a treatment is effective enough to be used routinely is to carry out a randomised controlled trial (RCT). In an RCT, patients are assigned randomly to two groups: a treatment group, given the new treatment and a control group, given a well-tried treatment or a placebo.

The HFEA has given time-lapse imaging an amber rating because although there have been studies looking at whether time-lapse imaging can improve birth rates, they don’t consider that there is enough evidence from RCTs to prove that time-lapse imaging improves your chance of having a baby.

It is important to consider though that CareMaps combines time-lapse imaging with the use of Care’s unique embryo ranking model. Care’s own data from a study published in 2017 of more than 23,000 treatment cycles showed a highly significant increase in births when CareMaps was used to select embryos for patients aged younger than 38 using their own eggs. A paper published by Care in 2019 showed that CareMaps is superior for selecting embryos most likely to result in a birth than standard selection methods.